SHP Shire

 
TIDMSHP 
 
Director Declaration 
 
June 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces 
that Flemming Ornskov, MD, MPH, Chief Executive Officer of the Company, was 
appointed to the Board of Directors of Waters Corporation on June 22, 2017. 
 
This notification is to satisfy the Company's obligations under LR 9.6.14R of 
the UK Listing Rules. 
 
Stephen Williams 
Deputy Company Secretary 
 
For further information please contact: 
 
Investor Relations 
 
Ian Karp                        ikarp@shire.com            +1 781 482 9018 
 
Robert Coates                   rcoates@shire.com          +44 1256 894874 
 
Media 
 
Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607 
 
Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083 
 
NOTES TO EDITORS 
 
About Shire 
 
Shire is the leading global biotechnology company focused on serving people 
with rare diseases. We strive to develop best-in-class products, many of which 
are available in more than 100 countries, across core therapeutic areas 
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage 
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary 
Angioedema; and a growing franchise in Oncology. 
 
Our employees come to work every day with a shared mission: to develop and 
deliver breakthrough therapies for the hundreds of millions of people in the 
world affected by rare diseases and other high-need conditions, and who lack 
effective therapies to live their lives to the fullest. 
 
www.shire.com 
 
 
 
END 
 

(END) Dow Jones Newswires

June 22, 2017 07:54 ET (11:54 GMT)

Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024

Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024